Cantor Fitzgerald analyst Brian Cheng maintained a Buy rating on Biocryst Pharmaceuticals on Thursday, setting a price target of $21, which is approximately 80.88% above the present share price of $11.61.
Cheng expects Biocryst Pharmaceuticals to post earnings per share (EPS) of -$0.24 for the fourth quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Moderate Buy rating of shares in BioCryst (NASDAQ:BCRX), with an average price target of $20.5.
The analysts price targets range from a high of $30 to a low of $14.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $49.96 million and a net profit of -$29.58 million. The company's market cap is $2.08 billion.
According to TipRanks.com, Cantor Fitzgerald analyst Brian Cheng is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of -0.4% and a 31.25% success rate.
BioCryst Pharmaceuticals , Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its drug candidates include rapivab, alpivab, rapiacta, peramiflu, BCX7353, BCX9930, BCX9250, Galidesivir, and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.